Tasly Pharmaceutical Group Company Limited operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Tasly Pharmaceutical Group Company Limited with three other
companies in this sector in China:
Shenzhen Neptunus Bioengineer
sales of 11.12 billion Chinese Renmimbi [US$1.61 billion]
of which 85%
was Pharmaceutical Distribution),
Shandong Buchang Pharmaceuticals Co Ltd
(11.65 billion Chinese Renmimbi [US$1.69 billion]
of which 88%
was Pharmaceutical Business), and
Shanghai Fosun Pharmaceutical (Group) Company Limited
(12.50 billion Chinese Renmimbi [US$1.82 billion]
of which 71%
was Pharmaceutical Manufacturing and R&D).
Tasly Pharmaceutical Group Company Limited reported sales of 13.22 billion Chinese Renmimbi (US$1.92 billion)
December of 2015.
increase of 5.2%
versus 2014, when the company's sales were 12.58 billion Chinese Renmimbi.
Sales at Tasly Pharmaceutical Group Company Limited have increased during each of the previous five years
(and since 2010, sales have increased a total of 184%).
Sales of Pharmaceutical and Medicine Manufacturing saw an increase
5.2% in 2015, from
6.05 billion Chinese Renmimbi to 6.36 billion Chinese Renmimbi.